FDA Drug · D-0702-2026

Levothyroxine Sodium Tablets, USP, 75 mcg (0.075 mg), 100 Tablets (10 x 10 unit dose blisters) per carton, Rx only, Packaged and Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268 USA. NDC: 0904-6951-61

Class II · Ongoing

Subpotent Drug

Affected lots / codes — check yours against thisLot# N02172, exp 07/2026; N02296, N02288, Exp. Date 12/2026

Recalling firm: Major Pharmaceuticals, Dublin, OH
Classification: Class II (temporary or reversible harm possible)
Status: Ongoing
Quantity: N/A
Distribution: Nationwide in the USA.
Recall initiated: July 13, 2026
Classified: July 17, 2026
Initiation: Voluntary: Firm initiated

Official source. This record is published by the U.S. FDA through the openFDA enforcement database. View the unmodified government record:
https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0702-2026%22

Important. Recalls target specific lots and codes — compare the affected lots above against your own product. This page reproduces public FDA data for readability; EveryRecall is independent and not affiliated with the FDA.

See every recall for this brand: Is LEVOTHYROXINE SODIUM recalled? →

Check this brand across all 8 databases →